At the clinical level, HER2 expression is correlated with poor clinicopathological prognostic outcomes, such as old age, advanced-stage disease, large tumor size, high tumor grade, lymphovascular space invasion, and poor survival rates [12-15]. This evidence concerns the gene ERBB2 and neoplasm.